Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > 4-1BB

4-1BB

Brief Information

Name:Tumor necrosis factor receptor superfamily member 9
Target Synonym:TNFRSF9,T-cell antigen ILA,ILA,TNF Receptor Superfamily Member 9,T-Cell Antigen 4-1BB Homolog,4-1BB Ligand Receptor,CD137 Antigen,CDw137,CD137,Interleukin-Activated Receptor, Homolog Of Mouse Ly63,Tumor Necrosis Factor Receptor Superfamily, Member 9,Tumor Necrosis Factor Receptor Superfamily Member 9,Induced By Lymphocyte Activation (ILA),Homolog Of Mouse 4-1BB,Receptor Protein 4-1BB,T Cell Antigen ILA,4-1BB
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:65
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
41B-H53H3 Human Human 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)
41B-H53H3-structure
41B-H53H3-sds
CHEK-ATF073 Human Human 4-1BB (Luc) HEK293 Reporter Cell
CHEK-ATP038 Human HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line
41B-H82F8 Human Biotinylated Human 4-1BB / TNFRSF9 Protein, Fc,Avitag™ (MALS verified)
41B-H82F8-structure
41B-H82F8-sds
41B-H52H9 Human Human 4-1BB / TNFRSF9 (24-86) Protein, His Tag
41B-H52H9-structure
41B-H52H9-sds
41B-H82E9 Human Biotinylated Human 4-1BB / TNFRSF9 (24-86) Protein, His,Avitag™
41B-H82E9-structure
41B-H82E9-sds
41B-C82E9 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque 4-1BB / TNFRSF9 Protein, Avitag™,His Tag (MALS verified)
41B-C82E9-structure
41B-C82E9-sds
41B-M82E8 Mouse Biotinylated Mouse 4-1BB / TNFRSF9 (24-211) Protein, Avitag™,His Tag
41B-M82E8-structure
41B-M82E8-sds
41B-C5253 Canine Canine 4-1BB / TNFRSF9 Protein, Fc Tag (MALS verified)
41B-C5253-structure
41B-C5253-sds
41B-H82E4 Human Biotinylated Human 4-1BB / TNFRSF9 (87-186) Protein, His,Avitag™ (MALS verified)
41B-H82E4-structure
41B-H82E4-sds
41B-H5253 Human Human 4-1BB / TNFRSF9 (87-186) Protein, Fc Tag (MALS verified)
41B-H5253-structure
41B-H5253-sds
41B-R52H3 Rat Rat 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)
41B-R52H3-structure
41B-R52H3-sds
41B-H52Hc Human Human 4-1BB / TNFRSF9 Protein, His Tag
41B-H52Hc-structure
41B-H52Hc-sds
41B-H82E6 Human Biotinylated Human 4-1BB / TNFRSF9 Protein, His,Avitag™(MALS verified)
41B-H82E6-structure
41B-H82E6-sds
41B-R52H9 Rabbit Rabbit 4-1BB / TNFRSF9 Protein, His Tag
41B-R52H9-structure
41B-R52H9-sds
41B-H5256 Human Human 4-1BB / TNFRSF9 Protein, Mouse IgG2a Fc Tag, low endotoxin
41B-H5256-structure
41B-H5256-sds
41B-M52H7 Mouse Mouse 4-1BB / TNFRSF9 Protein, His Tag
41B-M52H7-structure
41B-M52H7-sds
41B-M5258 Mouse Mouse 4-1BB /TNFRSF9 Protein, Fc Tag (MALS verified)
41B-M5258-structure
41B-M5258-sds
41B-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)
41B-C52H4-structure
41B-C52H4-sds
41B-H5258 Human Human 4-1BB / TNFRSF9 Protein, Fc Tag (MALS verified)
41B-H5258-structure
41B-H5258-sds
ACRO Quality

Part of Bioactivity data

CHEK-ATF073-Cell-based assay
 4-1BB FACS

Expression analysis of human 4-1BB on Human 4-1BB (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human 4-1BB (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human 4-1BB antibody.

CHEK-ATP038-Cell-based assay
 4-1BB FACS

FACS assay shows that Monoclonal UreluMab antibody, Human IgG4 can bind to HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line (CHEK-ATP038). HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

41B-H82E4-SPR
 4-1BB SPR

Biotinylated Human 4-1BB (87-186), His,Avitag (Cat. No. 41B-H82E4) captured on Biotin CAP - Series S sensor Chip can bind Utomilumab with an affinity constant of 0.452 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

41B-H82E6-SPR
 4-1BB SPR

Biotinylated Human 4-1BB Protein, His,Avitag (Cat. No. 41B-H82E6) captured on Biotin CAP-Series S sensor Chip can bind anti 4-1BB mAb with an affinity constant of 0.158 nM as determined in a SPR assay (Biacore T200) (Routinely tested) .

Customer Reviews

Synonym Name

TNFRSF9,4-1BB,CD137,CDw137,ILA

Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
HLX-35 HLX-35 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
CB-307 CB-307 Phase 1 Clinical Crescendo Bioscience Inc Neoplasms Details
BNA-035 BNA-035 Phase 1 Clinical Binacea Pharma Inc Solid tumours Details
RO-7122290 RO-7122290; RG-7827 Phase 2 Clinical F. Hoffmann-La Roche Ltd Colorectal Neoplasms Details
89Zr-S095012 89Zr-S-095012 Phase 1 Clinical Institut De Recherches Internationales Servier Solid tumours Details
BOS-342 PRS-342; BOS-342; PRS-342/BOS-342 Phase 2 Clinical Pieris Pharmaceuticals Solid tumours; Carcinoma, Hepatocellular Details
HK-010 HK-010; HK010 Phase 1 Clinical Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd Neoplasms Details
AP-203 AP-203; AP203 Phase 2 Clinical AP Biosciences Inc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
Acasunlimab PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 Phase 2 Clinical Genmab A/S, Biontech Se Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
ADG-206 ADG-206 Phase 1 Clinical Adagene (Suzhou) Ltd Neoplasms Details
QL-301 QL-301 Phase 1 Clinical Qlsf Biotherapeutics Inc Neoplasms Details
IMB-071703 IMB071703; IMB-071703 Phase 1 Clinical Beijng Immunoah Pharma Tech Co Ltd Solid tumours Details
BH-3120 BH-3120 Hanmi Pharmaceutical Co Ltd Solid tumours Details
Givastomig TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis Details
AGEN-2373 AGEN-2373 Phase 1 Clinical Agenus Inc Neoplasms Details
Ori-Bs-001 Ori-Bs-001 Phase 1 Clinical OriCell Therapeutics Co Ltd Solid tumours Details
Utomilumab PF-05082566; PF-5082566; PF-2566 Phase 3 Clinical Pfizer Inc, Pfizer Pharmaceuticals Ltd (China) Prostatic Neoplasms, Castration-Resistant; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Oropharyngeal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Solid tumours; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 2 Clinical Numab Therapeutics Ag, Cstone Pharmaceuticals Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Humanized CART Directed Against BCMA ARI-0002h Phase 2 Clinical Instituto De Salud Carlos Iii Multiple Myeloma Details
MP-0310 MP-0310; AMG-506 Phase 1 Clinical Molecular Partners Ag, Amgen Inc Solid tumours Details
CART-38(University of Pennsylvania) CART-38 Phase 1 Clinical University Of Pennsylvania Multiple Myeloma; Leukemia, Myeloid, Acute Details
ZG-033 ZG033 Phase 1 Clinical Hefei Hankemab Biotechnology Co Ltd Neoplasms Details
YH-004 YH-004 Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin Details
PE-0116 PE-0116 Phase 2 Clinical Shanghai HyaMab Biotech Co Ltd Solid tumours Details
GNC-035 quadr-specific antibody(baili) GNC-035 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
QL-1806 QL-1806 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
SGN-BB228 SGN-BB228 Phase 1 Clinical Seagen Inc Skin Melanoma; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Xirestomig ATG-101 Phase 1 Clinical Antengene Corporation Co Ltd Solid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Neoplasm Metastasis Details
Enristomig ES101; INBRX-105 Phase 2 Clinical Inhibrx Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Englumafusp alfa RG-6076; RO-7227166 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
ADG-106 ADG-106 Phase 2 Clinical Adagene (Suzhou) Ltd Solid tumours; Lymphoma, Non-Hodgkin Details
Exlinkibart LVGN-6051 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Papillomavirus Infections; Uveal melanoma; Sarcoma; Neoplasm Metastasis; Carcinoma, Hepatocellular Details
Urelumab BMS-66513; BMS-663513 Phase 2 Clinical Bristol-Myers Squibb Company Multiple Myeloma; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Gliosarcoma; Colorectal Neoplasms; Brain Neoplasms; Urinary Bladder Neoplasms; Lymphoma, B-Cell; Carcinoma, Transitional Cell; Skin Neoplasms; Neoplasms; Glioblastoma; Solid tumours; Leukemia; Head and Neck Neoplasms Details
PRS-344 PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 Phase 2 Clinical Pieris Pharmaceuticals Inc, Laboratoires Servier Solid tumours Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
Cinrebafusp alfa PRS-343 Phase 2 Clinical Pieris Pharmaceuticals Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms Details
DSP-107 DSP-107; KAHR-107 Phase 2 Clinical Kahr Medical Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
NBL-028 NBL028; NBL-028 Phase 1 Clinical Shanghai Xinshi Biological Medicine Co Ltd, Novarock Biotherapeutics Ltd Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Testicular Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Evunzekibart ATOR-1017 Phase 1 Clinical Alligator Bioscience Ab Solid tumours; Neoplasms Details
FS-120 FS-120 Phase 1 Clinical F-Star Neoplasms; Neoplasm Metastasis Details
CTX-471 CTX-471 Phase 1 Clinical Compass Therapeutics LLC Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Mesothelioma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
STA-551 STA-551 Phase 1 Clinical Chugai Pharmaceutical Co Ltd Solid tumours Details
HOT-1030 HOT-1030 Phase 1 Clinical Huabo Biopharm Co Ltd Solid tumours Details
QLF31907 QLF31907; QLF-31907 Phase 2 Clinical Qilu Pharmaceutical Co Ltd Neoplasms; Carcinoma, Transitional Cell; Melanoma Details
DF-003(Dingfu Biotarget) DF-003 Phase 1 Clinical Dingfu Biotarget Co Ltd Solid tumours; Lymphoma, Non-Hodgkin Details
TJ-L14B ABL-503; TJ-L14B/ABL503; ABL503 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours Details
BC 3425 BC-3425 Phase 1 Clinical Wuxi Zhikang Hongyi Biological Technology Co Ltd Solid tumours Details
BT-7480 BT-7480 Phase 2 Clinical Bicycle Therapeutics Solid tumours; Neoplasms Details
PM-1003 PM1003 Phase 2 Clinical Biotheus Inc Solid tumours Details
Sytalizumab TWP-101 Phase 1 Clinical Therawisdom Biopharma Co Ltd Solid tumours; Carcinoma, Transitional Cell; Melanoma Details
LM-24C5 LM-24C5 Phase 2 Clinical LaNova Medicines Ltd Solid tumours; Neoplasms Details
LBL-024 LBL-024; LBL024 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours; Neoplasms; Carcinoma, Neuroendocrine Details
Emfizatamab GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma Details
Delolimogene mupadenorepvec LOAd-703 Phase 2 Clinical Uppsala University, Lokon Pharma Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma Details
Tecaginlimab BNT-312; GEN-1042 Phase 2 Clinical Genmab A/S Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Nv Solid tumours; Lymphoma, B-Cell; Neoplasms Details
ALG.APV-527 ALG-APV-527; ADC-1016; ATOR-1016; ALG.APV-527 Phase 2 Clinical Aptevo, Alligator Bioscience Ab Solid tumours; Neoplasms Details
PM-1032 PM1032; PM-1032 Phase 2 Clinical Biotheus Inc, Shanghai Genechem Co Ltd Neoplasms Details
FS-222 FS-222 Phase 1 Clinical F-star Beta Ltd Neoplasms; Neoplasm Metastasis Details
YH-32367 ABL105; YH-32367 Phase 2 Clinical Abl Bio Inc Solid tumours; Stomach Neoplasms; Breast Neoplasms Details
EU-101 EU-101; NOV-1801 Phase 2 Clinical Eutilex Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Cedarizumab Phase 1 Clinical Therawisdom Biopharma Co Ltd Solid tumours; Carcinoma, Transitional Cell; Melanoma Details
FTL-001 FTL001; FTL-001 Phase 1 Clinical Xikang (Wuhan) Biomedicine Co Ltd, Sound(Chengdu)Biopharmacauticals Co Ltd Solid tumours Details
IBI-319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
HBM-7008 HBM7008; HBM-7008; R-7008 Phase 1 Clinical Harbour Biomed Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message